Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Weight Loss 1Preleukemia 1Ovarian Neoplasms 1Obesity 1Myelodysplastic Syndromes 1Malnutrition 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Cisplatin 115Radiotherapy 83Paclitaxel 77Fluorouracil 61Carboplatin 41Drug Therapy 34pembrolizumab 33Irinotecan 33tislelizumab 27Docetaxel 26toripalimab 23Oxaliplatin 23Neoadjuvant Therapy 23Radiation 20sintilimab 19camrelizumab 19130-nm albumin-bound paclitaxel 18Esophagectomy 17Capecitabine 17Surgical Procedures, Operative 15Leucovorin 15Nivolumab 14Cetuximab 14TP protocol 12S 1 (combination) 12Radiotherapy, Intensity-Modulated 12Albumin-Bound Paclitaxel 12nimotuzumab 11apatinib 10anlotinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Esophageal Squamous Cell Carcinoma × Sampling Studies × Clear all
NCT04666090 2025-05-15

Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Active not recruiting
42 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡